Of note, such BRCAness correlates positively with tumor response rates to alkylating chemotherapy drugs like cisplatin – as indeed does PARP1/2 gene knockout in mice – yet negatively with responses to taxane-based chemotherapies (73). Here, PARP1 is linked to neoplasm.